Education
About Us
Working with TipRanks
Follow Us
Xortx Therapeutics (XRTX)
:XRTX
XRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $2.51
Previous CloseN/A
Volume19.17K
Average Volume (3M)32.58K
Market Cap
$4.11M
Enterprise Value$3.28M
Total Cash (Recent Filing)$1.06M
Total Debt (Recent Filing)$80.47K
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Nov 12, 2025EPS Estimate
-0.17Last Dividend Ex-Date
Jan 31, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding5,212,218
10 Day Avg. Volume43,429
30 Day Avg. Volume32,582
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$13.88Price Target Upside1635.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
XORTX Therapeutics Inc News
XRTX FAQ
What was Xortx Therapeutics’s price range in the past 12 months?
Xortx Therapeutics lowest stock price was $0.66 and its highest was $2.51 in the past 12 months.
What is Xortx Therapeutics’s market cap?
Xortx Therapeutics’s market cap is $4.11M.
When is Xortx Therapeutics’s upcoming earnings report date?
Xortx Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 36 days.
How were Xortx Therapeutics’s earnings last quarter?
Xortx Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.19.
Is Xortx Therapeutics overvalued?
According to Wall Street analysts Xortx Therapeutics’s price is currently Undervalued.
Does Xortx Therapeutics pay dividends?
Xortx Therapeutics pays a Quarterly dividend of $0.075 which represents an annual dividend yield of N/A. See more information on Xortx Therapeutics dividends here
What is Xortx Therapeutics’s EPS estimate?
Xortx Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Xortx Therapeutics have?
Xortx Therapeutics has 5,212,218 shares outstanding.
What happened to Xortx Therapeutics’s price movement after its last earnings report?
Xortx Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.023%.
Which hedge fund is a major shareholder of Xortx Therapeutics?
Currently, no hedge funds are holding shares in XRTX
Company Description
Xortx Therapeutics
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Quest Pharmatech
―
Algernon Pharmaceuticals
―
Appili Therapeutics Inc Class A
―
Rakovina Therapeutics Inc
―
Marvel Biosciences Corp
―
Ownership Overview
Options Prices
Currently, No data available
---